This is the authors' abstract. We don't add key points for this paper.
Background: Phenytoin is a widely used, cost-effective anticonvulsant with a narrow therapeutic range, requiring close monitoring to avoid toxicity. Our aim was to investigate phenytoin toxicity in an emergency department setting, focusing on clinical features, management, and outcomes. Methods: This retrospective cohort study reviewed charts from 2011 to 2021 for all cases of oral phenytoin with levels above the therapeutic range (>79.0 μmol/L or 20 mg/L). Patients were included if they exhibited clinical signs and symptoms consistent with phenytoin toxicity. Results: Of 2245 patients who had phenytoin levels sent, 264 (11.8%) had serum phenytoin levels exceeding 79.0 μmol/L; only 42 patients met the clinical inclusion criteria. Patient ages ranged from 1 to 77 years (mean: 37.7 years; standard deviation: ±24.2), with a male predominance (59.5%). Acute overdose accounted for 54.8% (23 cases). All patients presented with neurological complaints, including ataxia (50.0%), dizziness (42.9%), and seizures (33.3%). None presented with cardiological complaints. Electrocardiogram was done only for 16 patients, of whom 3 had abnormal findings. Among these 42 patients, initial phenytoin levels ranged from 82.7 to 409.7 μmol/L (mean: 130.3; interquartile range: 68.1). Only one (2.4%) patient received multiple-dose activated charcoal (MDAC). The majority (85.7%) required hospital admission. There was one (2.4%) mortality among the included patients. Conclusion: Among patients with elevated phenytoin levels, only 15.9% exhibited clinical symptoms. However, majority of these patients needed hospital admission. MDAC was underutilized as a management modality.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ellouze et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: